Keros Therapeutics, Inc. (KROS) shares are experiencing an uptick today, likely influenced by recent institutional interest. Alkeon Capital Management LLC significantly increased its stake in the company by 18.7% during the third quarter, as reported in a recent SEC filing. This move by a major institutional investor may have bolstered market confidence in Keros, contributing to the stock's upward momentum. Additionally, other institutional investors, such as Mirae Asset Global Investments Co. Ltd. and KBC Group NV, have also increased their holdings in Keros, further indicating positive sentiment among large investors.
Keros Therapeutics' stock is currently trading at $60.25, reflecting a 2.90% increase from its previous close of $58.55.